Accordingly, an ongoing clinical trial will analyze the cardiovascular effect of GLP1-RAs, SGLT2i, and their combination in T2DM patients, and oxidative stress markers will be measured (NCT03878706). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.